BIOSTRATEGIES LC
- JONESBORO, AR 72401
- Partnership or Limited Liability Partnership
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
- Veteran-Owned Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
BIOSTRATEGIES LC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About BIOSTRATEGIES LC
- Headquarters
- JONESBORO, AR 72401
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIPE6MEQZRFW63
- CAGE4BJ87
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 22 awards
- Total awarded
- $18,287,965
- By phase
- SBIR Phase I: 14
- SBIR Phase II: 8
- By agency
- Department of Health and Human Services: 18
- Department of Agriculture: 4
- Active projects
- 1 project
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 1 project
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 1
- 2023: 2
- 2022: 1
- 2020: 2
- 2019: 1
- 2018: 1
- 2017: 3
- 2016: 1
- 2015: 1
- 2014: 3
- 2013: 1
- 2011: 1
- 2010: 2
- 2008: 1
- 2007: 1
Awards (most recent first)
Treatment of GM1 gangliosidosis CNS manifestations by AAV systemic expression of lectin-enhanced enzyme
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $1,500,000
Sep 15, 2025 – Aug 30, 2027
- Active
- Ends Aug 2027
Solicitation PA24-245 (2024) · Topic 102
Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $295,923
Sep 20, 2023 – Aug 31, 2024
Solicitation PA22-176 (2022) · Topic NICHD
Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,998,067
Sep 15, 2023 – Aug 31, 2025
Solicitation PA22-176 (2022) · Topic 105
Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $390,497
Jul 15, 2022 – Jun 30, 2023
Solicitation PA21-259 (2021) · Topic 105
Treatment of muscular symptoms in Pompe rare disease via lectin assisted ERT delivery
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $250,000
Aug 15, 2020 – Jul 30, 2021
Solicitation AR20-003 (2019) · Topic NIAMS
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $2,049,999
Apr 9, 2020 – Mar 31, 2022
Solicitation PA19-272 (2019) · Topic NICHD
Lectin-mediated ERT Delivered to Cardiac Tissue in Fabry Disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $293,232
Sep 1, 2019 – Aug 31, 2020
Solicitation PA18-574 (2018) · Topic NHLBI
MPS I Skeletal Disease Therapy with Novel Lectin-delivered Replacement Enzyme
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $225,000
Jul 1, 2018 – Jun 30, 2019
Solicitation AR18-005 (2017) · Topic NIAMS
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $2,384,044
Sep 30, 2017 – Jul 31, 2019
Solicitation PA16-302 (2016) · Topic 101
Improving MPS I ERT Efficacy through Lectin Mediated Delivery
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $1,237,037
Sep 30, 2017 – Jul 31, 2019
Solicitation PA16-302 (2016) · Topic 101
Enzyme replacement therapy for GM1 gangliosidosis lysosomal rare disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $2,438,483
Sep 15, 2017 – Aug 31, 2019
Solicitation PA15-269 (2015) · Topic 107
Enzyme Replacement Therapeutics for Rare Childhood Genetic Diseases: An ERT Delivery System that Mitigates Immune-sensitization
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $225,000
Jul 6, 2016 – Jun 30, 2018
Solicitation PA14-071 (2014) · Topic NICHD
Enzyme replacement therapy for Sanfilippo A lysosomal rare disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2015 · $1,491,165
Jul 15, 2015 – Jun 30, 2019
Solicitation PA14-071 (2014) · Topic 107
Improving MPS I ERT Efficacy through Lectin-Mediated Delivery
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $644,231
Jul 1, 2014 – Jun 30, 2016
Solicitation PA13-088 (2014) · Topic 100
Targeted Enzyme Replacement Therapy for Rare Forms of Osteogenesis Imperfecta
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $223,352
Solicitation AR14-005 (2014) · Topic NIAMS · Research partner: Stub
Enzyme Replacement Therapy for GM1 Gangliosidosis Lysosomal Rare Disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $225,000
Solicitation PA13-234 (2014) · Topic NINDS · Research partner: Stub
MyNutritionPlanner: Development and Evaluation of an Innovative Software Approach
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $285,783
Solicitation PA12-088 (2013) · Topic NINDS · Research partner: Stub
Plant Produced Porcine IL-12 Vaccine Adjuvant for Swine Flu and Other Viral Diseases
SBIR Phase II · Department of Agriculture · 2011 · $460,000
Solicitation USDA-NIFA-SBIR-00339 (2011) · Topic 8.2
A Novel Plant Cell Bio-Production Platform for Therapeutic Proteins
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $151,190
Solicitation PHS2010-2 (2010) · Topic NIGMS
Plant Produced Porcine IL-12 Vaccine Adjuvant for Swine Flu and Other Viral Diseases
SBIR Phase I · Department of Agriculture · 2010 · $90,000
Topic 8.2
Plant-based BioProduction of Chicken IL-12 Adjuvant for Bird Flu Vaccine
SBIR Phase II · Department of Agriculture · 2008 · $350,000
Plant-based BioProduction of Chicken IL-12 Adjuvant for Bird Flu Vaccines
SBIR Phase I · Department of Agriculture · 2007 · $79,962
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard
SAM.gov reports this entity as small under 1 of 1 NAICS code. Size is determined per code (SBA size standards).
Socio-economic status
Self-represented in SAM.gov. WOSB and EDWOSB set-asides need SBA certification (13 CFR 127.300); SDVOSB and VOSB need SBA VetCert (13 CFR part 128). Confirm current certification before relying on it.
Learn more about small business set-asidesProduct & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with BIOSTRATEGIES LC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.